|Bid||1,981.50 x 0|
|Ask||1,983.00 x 0|
|Day's Range||1,976.00 - 2,043.00|
|52 Week Range||1,976.00 - 2,703.00|
|Beta (5Y Monthly)||-0.11|
|PE Ratio (TTM)||13.37|
|Earnings Date||Feb 24, 2022|
|Forward Dividend & Yield||0.38 (1.87%)|
|Ex-Dividend Date||Aug 19, 2021|
|1y Target Est||27.73|
Subscribe to Yahoo Finance Plus to view Fair Value for HIK.LLearn more
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that its venture capital arm, Hikma Ventures has led a $11 million USD round of financing for NuvoAir, a leading digital health company for chronic disease management and decentralized clinical trials that focuses on complex patients, initially targeting respiratory conditions such as COPD and asthma. The investment is an extension of the Series A round that was previously announced by NuvoAir in June 2021. Th
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces that it has agreed to acquire the Canadian assets of Teligent Inc. (Teligent) for $45.75 million. The transaction is expected to be completed before the end of the first quarter of 2022.
Hikma Pharmaceuticals PLC ("Hikma"), the multinational pharmaceutical company, announces the launch of Hikma 503B – a new outsourced sterile compounding business focused on providing high quality, ready-to-administer injectable medications that are customized to the specific needs of patients in the United States.